The program will be provided soon, and includes current topics in the areas of renal, arterial hypertension, cardiovascular and metabolic.  Some topics that will be covered:

​

• SGLT2i mechanisms, consequences and new indications, in diabetic and non-diabetic patients.

• GLPA-RA: news.

• Insulin management in diabetic kidney disease and what role they play considering the wide range of new drugs.

• Finerenone, mineralocorticoid receptor antagonists and angiotensin antagonists in diabetic patients.

• New advances in the metabolism and management of vitamin D.

• The new generation of treatment for patients with diabetic kidney disease.

• Bone mineral disease in the era of personalized medicine.

• Interrelationships between kidney, heart and intestine.

• Difficult-to-control hypertension: what to do next?

• New therapeutic options in hyperkalemia.

• From the laboratory to the patient: what's new in SLE and glomerulopathies.

• Management of CKD in an aging society and non-dialytic treatment options.

• Awareness and advances in the diagnosis of Fabry disease.